A5073335312- Hepatitis C virus research
- Renal Transplantation Outcomes and Treatments
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Transplantation: Methods and Outcomes
- HIV/AIDS drug development and treatment
- CAR-T cell therapy research
- Systemic Lupus Erythematosus Research
- COVID-19 Clinical Research Studies
- Hepatitis B Virus Studies
- T-cell and B-cell Immunology
- Viral Infections and Immunology Research
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Endoplasmic Reticulum Stress and Disease
- Long-Term Effects of COVID-19
- Cytomegalovirus and herpesvirus research
- Diet, Metabolism, and Disease
- interferon and immune responses
- Immune responses and vaccinations
- Atherosclerosis and Cardiovascular Diseases
- Coral and Marine Ecosystems Studies
- Crustacean biology and ecology
- Dermatological and COVID-19 studies
- Multiple and Secondary Primary Cancers
Massachusetts General Hospital
2015-2025
Harvard University
2018-2025
Hepatitis C virus (HCV) is the most common cause of mixed cryoglobulinemia syndrome (MCS). The efficacy and safety all‐oral direct‐acting antiviral (DAA) therapy in HCV‐associated MCS (HCV‐MCS) largely unknown. authors studied case series patients with HCV‐MCS who were treated sofosbuvir‐based regimens historical controls pegylated interferon ribavirin a single health care network. was defined by circulating cryoglobulin associated systemic vasculitis symptoms. Renal involvement (n = 7)...
Coronavirus disease 2019 (COVID-19) leads to elevated liver biochemistries in approximately half of patients on presentation. To date, data are limited regarding the trend over course illness. We aimed evaluate trend, etiology, and outcomes associated with COVID-19.A total 60 COVID-19 were admitted between March 21 28, 2020. The mean age was 57 years, 65% male, 28% Hispanic. At study conclusion, 6 deceased, 28 discharged, 26 remained admitted. Patients who followed for a median 12 days. Of...
•Aptamer-based profiling platform used to find proteins that non-invasively identify significant fibrosis in 316 adults with NAFLD.•An 8-protein panel can distinguish NAFL/NASH stage 0-1 from 2-4 an AUROC of 0.87-0.89.•The ADAMTSL2 protein alone 0.83-0.86.•Both the and showed superior performance NAFLD score fibrosis-4 score. Background & AimsIdentifying non-alcoholic fatty liver disease (NAFLD) is essential predict liver-related outcomes guide treatment decisions. A protein-based signature...
Significance Statement Single-center trials and retrospective case series have reported promising outcomes transplanting kidneys from donors with hepatitis C virus (HCV) infection into HCV-negative recipients, although concerns remain about immunologic complications. In this first multicenter trial, 30 HCV-uninfected adults received a kidney an HCV-viremic deceased donor were cured of HCV 8-week regimen coformulated glecaprevir pibrentasvir initiated 2–5 days post-transplant. Three patients...
Approaches to manage nonalcoholic fatty liver disease (NAFLD) are limited by an incomplete understanding of pathogenesis. The aim this study was identify hepatic gene-expression patterns associated with different injury in a high-risk cohort adults obesity. Using the NanoString Technologies (Seattle, WA) nCounter assay, we quantified expression 795 genes, hypothesized be involved fibrosis, inflammation, and steatosis, tissue from 318 Liver specimens were categorized into four distinct NAFLD...
Viral hepatitis remains a major global health issue, with chronic B (HBV) and C (HCV) causing approximately 1 million deaths annually, primarily due to liver cancer cirrhosis. More than 1.5 people contract HCV each year, disproportionately affecting vulnerable populations, including American Indians Alaska Natives (AI/AN). While direct-acting antivirals (DAAs) are highly effective, timely accurate diagnosis challenge, particularly in resource-limited settings. The current two-step testing...
Coinfection with human immunodeficiency virus (HIV) accelerates hepatitis C (HCV)-related liver fibrosis. Macrophages are triggered during both viral infections and critical in inflammation/fibrogenesis. Liver fibrosis strongly associates serum soluble CD163 (sCD163, a macrophage activation marker); comprehensive evaluation HIV/HCV coinfection is lacking.
The practice of transplanting hepatitis C (HCV)-infected livers into HCV-uninfected recipients has not previously been recommended in transplant guidelines, part because concerns over uncontrolled HCV infection the allograft. Direct-acting antivirals (DAAs) provide an opportunity to treat donor-derived HCV-infection and should be administered early posttransplant period. However, evidence on safety efficacy immediate DAA treatment approach, including how manage logistical barriers...
Microelimination of the hepatitis C virus (HCV) among men who have sex with (MSM) could be complicated by continuous external introductions and emergence phylogenetic clusters harbouring clinically significant resistance-associated substitutions (RAS). To investigate international clustering prevalence transmission RAS, we aimed to analyse whole-genome HCV sequences from MSM a recently acquired infection participated in large, treatment trial.For this analysis, obtained 128 had within past...
Summary The role of the endogenous interferon ( IFN ) system has been well characterized during ‐based therapy for chronic hepatitis C virus HCV infection; less is known direct‐acting antivirals DAA s). In this phase 3b open‐label study, we assessed changes in ‐stimulated genes ISG s) non‐cirrhotic treatment‐naïve or peg / RBV ‐experienced ‐ GT 1a‐infected patients receiving paritaprevir/ritonavir/ombitasvir + dasabuvir ribavirin (Pr OD R) 12 weeks. expression was quantified from peripheral...
Transplanting kidneys from hepatitis C virus (HCV) viremic donors into HCV-negative patients (HCV D-RNA-positive/R-negative) has evolved experimental to "standard-of-care" at many centers. Nevertheless, most data derive single centers and provide only short-term follow-up.The Multicenter Study Transplant Hepatitis C-Infected Kidneys (MYTHIC) study was a multicenter (7 sites) trial of HCV D-RNA-positive/R-negative kidney transplantation (KT) followed by 8 weeks glecaprevir/pibrentasvir (G/P)...
Kochar, Bharati MD, MSCR1,2; Ufere, Nneka N. MD1,2; Nipp, Ryan MPH2,3; Gustafson, Jenna L. MS1; Carolan, Peter MD1; Ritchie, Christine S. MSPH2,4 Author Information
Long wait times for kidney transplants have prompted investigation into strategies to decrease the discarding of potentially viable organs. Recent reports suggest that kidneys from hepatitis C virus (HCV)-infected donors may be transplanted HCV-naive followed by direct-acting antiviral therapy.This was a pilot clinical trial transplant HCV-infected recipients with preemptive use elbasvir and grazoprevir 12 weeks. The primary outcome sustained virologic response weeks after completion...
Background: COVID-19 is associated with higher morbidity and mortality in patients chronic liver diseases (CLDs). However, our understanding of the long-term outcomes CLD limited. Methods: We conducted a multicenter, observational cohort study adult who were diagnosed before May 30, 2020, to determine clinical outcomes. used control group confirmed negative for COVID-19. Results: followed 666 (median age 58 years, 52.8% male) median 384 (interquartile range: 31–462) days. The was 8.1%; 3.6%...
Background There is an unmet need for interferon-and ribavirin-free treatment chronic HCV infection in patients with comorbidities including cardiovascular disease (CVD). The aim of this study was to evaluate the rates sustained virological response (SVR) and adverse events a cohort nosocomially acquired genotype-1b following 12 weeks therapy fixed-dose combination (FDC) ledipasvir/ sofosbuvir (LDV/SOF). Methods This prospective, single-centre, open-label five non-cirrhotic significant...
Abstract Long waiting times for kidney transplant (KT) and the high risk of mortality on dialysis have prompted investigation into strategies to utilize hepatitis C virus (HCV)‐infected organs decrease discard rates potentially viable kidneys. Due opioid epidemic, number HCV‐infected donors has increased significantly. With development direct‐acting antiviral therapies HCV infection, now more than 95% patients who received treatment are cured. Experimental trials used therapy treat infection...
Our previous Multicenter Trial to Transplant HCV-infected Kidneys (MYTHIC) observed that 100% of hepatitis C virus (HCV)-uninfected patients who received a kidney from an deceased donor were cured HCV with 8-week regimen glecaprevir and pibrentasvir (G/P) initiated 2-5 days after transplantation. Following acute chronic infection HCV, immune system perturbations have been reported persist even viral clearance. The aim this study was determine whether viremic recipients in the MYTHIC...